The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Universal Biosensors (UBI) has signed a distribution agreement with Vines to Vintages for the distribution of its wine-testing platform, Sentia, in Canada
  • Sentia analyses sulfur dioxide in post-fermentation red or white wine
  • The agreement is for three years and includes standard renewal and termination options
  • On the market, UBI is up 1.96 per cent and is trading at 52 cents per share

Universal Biosensors (UBI) has signed a distribution agreement with Vines to Vintages for the distribution of its wine-testing platform device, Sentia, in Canada.

Vines to Vintages is an independent wine laboratory performing analysis for wineries in Canada and United States. It also sells winemaking supplies and equipment.

Sentia analyses sulfur dioxide in post-fermentation red or white wine. The product is then able to display, through a touchscreen, the test results in under a minute.

Sulfur dioxide is added in the winemaking process to protect the wine from oxidation and bacterial spoilage.

The agreement is for three years and includes standard renewal and termination options.

UBI CEO John Sharman said this is another positive step in the commercialisation of Sentia globally.

“Vines to Vintages is well represented in all of Canada’s wine regions and has access to 700 wineries. The deal includes an initial commitment to purchase
Sentia devices and strips which will be delivered over the course of the next few weeks,” he said.

“We believe the possibility of Sentia’s future testing capability for Glucose,
Fructose, Malic Acid and others will add significant value to the winemaking industry,” he added.

UBI is currently negotiating terms with a number of key industry players around the world and looks forward to reporting additional distribution partnerships in the future.

On the market, UBI is up 1.96 per cent and is trading at 52 cents per share at 2:49 pm AEDT.

UBI by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system